Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.

BACKGROUND: Tildrakizumab is a humanized, IgG1/κ antibody that interacts with the p19 subunit of interleukin 23. It is approved for the treatment of moderate-to-severe plaque psoriasis. Real-world evidence on the effectiveness and safety of tildrakizumab is limited. OBJECTIVES: To assess the effectiveness and safety of tildrakizumab at 24 weeks in patients with moderate-to-severe plaque psoriasis in routine clinical practice. METHODS: Retrospective, observational, multicentre study including adult patients with moderate-to-severe plaque psoriasis treated with tildrakizumab under real-life conditions. Patient data were extracted from anonymized electronic medical records. Statistical analysis was performed using SPSS22. RESULTS: A total of 190 patients were included. About 53.9% were men with a mean age of 51.45 (SD 3.9) and a mean BMI of 29.13 (SD 6.21). About 79.8% (132 out of 190) of patients had previously received biological therapy (BT) and 17.3% (33 out of 191) had psoriatic arthritis. Baseline PASI was 10.7 (SD 6.53). Up to 109 patients reached Week 24 and at this point mean baseline PASI decreased to 1.7 (SD 4.8), representing an 88.79% mean PASI reduction. At 6 months, 87.1% and 40.3% of the treated patients achieved PASI ≤3 and ≤1, respectively. At Week 24 mean BSA decreased from 13.2 (SD 10.07) to 1.6 (SD 4.40) and mean DLQI went from 12.5 (SD 7.12) to 1.2 (SD 3.27). Multivariate analysis showed no differences when effectiveness was correlated with gender, obesity, psoriatic arthritis or prior exposure to BT. The rate of adverse events (AE) was 5.9% (11 out of 190), where infections were the most frequent AE (4 out of 11). One patient suffered a haemorrhagic ictus and one patient died due to causes unrelated to the study. CONCLUSION: Tildrakizumab was effective and safe in a large cohort of patients with moderate-to-severe plaque psoriasis treated in a routine clinical setting.

Maculopapular eruptions associated to COVID-19: A subanalysis of the COVID-Piel study.

A previous study has defined the maculopapular subtype of manifestations of COVID-19. The objective of our study was to describe and classify maculopapular eruptions associated with COVI-19. We carried out a subanalysis of the maculopapular cases found in the previous cross-sectional study. Using a consensus, we defined seven clinical patterns. We described patient demographics, the therapy received by the patient and the characteristics of each pattern. Consensus lead to the description of seven major maculopapular patterns: morbilliform (45.5%), other maculopapular (20.0%), purpuric (14.2%), erythema multiforme-like (9.7%), pytiriasis rosea-like (5.7%), erythema elevatum diutinum-like (2.3%), and perifollicular (2.3%). In most cases, maculopapular eruptions were coincident (61.9%) or subsequent (34.1%) to the onset of other COVID-19 manifestations. The most frequent were cough (76%), dyspnea (72%), fever (88%), and astenia (62%). Hospital admission due to pneumonia was frequent (61%). Drug intake was frequent (78%). Laboratory alterations associated with maculo-papular eruptions were high C-reactive protein, high D-Dimer, lymphopenia, high ferritin, high LDH, and high IL-6. The main limitation of our study was the impossibility to define the cause-effect relationship of each pattern. In conclusion, we provide a description of the cutaneous maculopapular manifestations associated with COVID-19. The cutaneous manifestations of COVID-19 are wide-ranging and can mimic other dermatoses.

Effectiveness and safety of Methotrexate in psoriasis: an eight-year experience with 218 patients.

BACKGROUND: Methotrexate (MTX), a traditional antipsoriatic drug, is very frequently used either as monotherapy or in combination with other systemic drugs. OBJECTIVES: To assess the effectiveness and safety of MTX in psoriasis in usual clinical practice. METHODS: We conducted a retrospective study. We performed an electronic and manual chart review of patients treated with MTX in the Psoriasis Unit of our Hospital from January 2007 to December 2014. Demographic and clinical data, PASI/DLQI scores and reasons for suspension of all patients treated with MTX in usual clinical practice were recorded. RESULTS: Two hundred and eighteen patients were included. MTX was administered in 67% of cases as the first systemic treatment. The average treatment duration was 17.2 ± 13.6 months. All patients were subjected to clinical and laboratory monitoring. About 33.5% of them achieved a reduction of 75% or more of the initial PASI at week 12, 34.9% at week16, 44.7% at week 24, and 52.8% at week 48. A 3.3% had to discontinue the therapy due to analytical hepatic (2.8%) or renal (0.5%) abnormalities. Only one patient experienced severe interstitial pneumonitis and none required liver biopsy. CONCLUSIONS: MTX is an effective and safe option for the treatment of psoriasis in the real-world clinical practice.

Metotrexato en el tratamiento de la psoriasis / Methotrexate in the treatment of psoriasis

La psoriasis es una enfermedad inflamatoria, de base genética, mediada inmunológicamente, con manifestaciones cutáneas preeminentes y asociada a comorbilidades sistémicas (osteoarticular, cardiovascular, diabetes, obesidad, enfermedad inflamatoria intestinal, cardiopatía isquémica, síndrome metabólico, ictus, hepatopatía, enfermedad psiquiátrica), lo que hace que su limitación patológica se extienda más allá de la piel. Afecta aproximadamente al 2,4% de la población española y, dado que actualmente no se dispone de curación definitiva, se requiere terapia a lo largo de la vida del paciente ajustada al control clínico de esta. Los tratamientos sistémicos clásicos (metotrexato, acitetrina, ciclosporina, luz ultravioleta), junto con las denominadas terapias biológicas disponibles actualmente (etanercept, infliximab, adalimumab, ustekinumab), permiten al dermatólogo disponer de un arsenal terapéutico más amplio y disponer, por lo tanto, de mayores posibilidades de control de pacientes con psoriasis grave y/o extensa. El metotrexato, un fármaco clásico en la terapia antipsoriásica, sigue siendo de gran utilidad, tanto en monoterapia como asociado a otros fármacos sistémicos, en especial como rescate o combinación con los biológicos. El objetivo de este artículo es establecer el papel del metotrexato en el tratamiento de la psoriasis (AU)

Psoriasis is a genetic, immune-mediated inflammatory disease with preeminent cutaneous manifestations associated with systemic comorbidities (osteoarticular, cardiovascular, diabetes, obesity, intestinal inflammatory disease, ischemic heart disease, metabolic syndrome, stroke, liver disease, psychiatric disease). Consequently, this disease has repercussions that go far beyond the skin. Psoriasis affects approximately 2.4% of the Spanish population. Currently, there is no definitive cure and consequently patients require lifelong treatment, with period adjustments based on the results of monitoring. Classic systemic therapies (methotrexate, acitretin, cyclosporine, ultraviolet light), together with currently available biological therapies (etanercept, infliximab, adalimumab, ustekinumab) provide dermatologists with a broader therapeutic armamentarium and therefore with greater possibilities for controlling severe and/or extensive psoriasis. Methotrexate, a classic drug in anti-psoriatic therapy, continues to be highly useful both in monotherapy and in combination with other systemic drugs, especially as rescue therapy or combined with biological agents. The aim of this article is to establish the role of methotrexate in the treatment of psoriasis (AU)

MC1R gene variants and sporadic malignant melanoma susceptibility in the Canary Islands population.

Several MC1R variants are associated with increased risk of malignant melanoma (MM) in a variety of populations. We aim to examine the influence of the MC1R variants (RHC: D84E, R151C, R160W; NRHC: V60L, R163Q and the synonymous polymorphism T314T) on the MM risk in a population from the Canary Islands. Overall, 1,046 Caucasian individuals were included in the study. A thousand of them were genotyped for MC1R variants: 509 were sporadic MM patients and 491 were healthy control subjects from general population. The analysis was adjusted for age, sex, hair colour, eye colour, skin phototype and ancestry. We found that carriers of the R151C and R163Q variants were at an increased risk for melanoma OR 2.76 (1.59-4.78) and OR 5.62 (2.54-12.42), respectively. The risk of carrying RHC variants was 3.04 (1.90-4.86). Current study confirms the increased MM risk for R151C carriers. It also supports the association between R163Q variant and MM risk in the population on the Canary Islands, as opposed to reported on northern populations. These results highlight the importance of the sample population selection in this kind of studies.

Treatment of folliculitis decalvans with tacrolimus ointment.

Folliculitis decalvans is an embarrassing and challenging disease with no established treatment guidelines. In this paper, we described four patients with this disease treated successfully with Tacrolimus ointment. All of them showed significant control of the condition, stopping inflammatory lesions and progression of the disease, although weak transitory outbreaks of inflammatory lesions were observed in some cases. Alopecia and tufted hairs remained unchanged. The discontinuation of the therapy produced rapid relapses in all cases. Close monitoring of these patients is recommended due to the potential risk of malignant transformation of the disease.

The D84E variant of the alpha-MSH receptor 1 gene is associated with cutaneous malignant melanoma early onset.

BACKGROUND: Alpha-melanocyte-stimulating hormone receptor 1 (MC1R) has an important role in skin pigmentation and variants of the gene have been established as independent risk factors for susceptibility to cutaneous malignant melanoma. OBJECTIVE: To explore whether variants of the gene also influence the onset of the disease. METHODS: We analyzed 285 melanoma patients of European ancestry for common variation in codon 84 (D84E) of the alpha-MSH receptor 1 gene, which is known to have functional consequences in MC1R protein activity. RESULTS: The mean age difference at diagnosis between MC1R 84E carriers and non-carriers was 9 years (95% confidence interval [CI]: 2-17; p=0.012), with 84E non-carrier patients being older. After adjusting for gender, Clark's level, phototype, eyes and hair colour, the risk for cutaneous malignant melanoma at any age was 2.07 times higher (95% CI: 1.21-3.52; p=0.008) among MC1R 84E carriers. Enrolment criteria, geographical origin, Clark's levels and Breslow's indexes were similar between MC1R 84E carriers and non-carriers. Further analyses based on the Clark level and Breslow's index, both indicative for cancer invasion, reasonably supported an unbiased selection of patients during the study enrolment. Additional exon re-sequencing of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene in MC1R 84E carriers ruled out the presence of high penetrance mutations that have previously been associated with early onset of the disease. CONCLUSION: Although our findings need to be confirmed by independent and larger studies we have described for the first time the association of D84E variant of the alpha-MSH receptor 1 gene as an independent risk factor for an earlier onset of cutaneous malignant melanoma.

Pilomatricoma pigmentado / Pigmented pilomatricoma

Una mujer de 49 años mostraba en la frente un nódulo con aspecto de quiste epidermoide. El estudio histopatológico mostró un pilomatricoma con abundante pigmento melánico en el parénquima y el estroma. Esto es un hallazgo infrecuente en los pilomatricomas que puede ser motivo de confusión y desafío diagnóstico en caso de realizar biopsia parcial de los mismos (AU)

Estudio clínico y alergológico en pacientes con manifestaciones cutáneas minor de dermatitis atópica / Clinical and alergological study in patients with 'minor' cutaneous manifestations of atopic dermatitis

Antecedentes: los signos menores de dermatitis atópica pueden ser la única manifestación del proceso o formar parte del cuadro florido. Su importancia para el diagnóstico ha sido objeto de múltiples trabajos. Objetivo: relacionar las manifestaciones cútaneas menores de dermatitis atópica con la constitución atópica, historia personal y familiar y la interrelación con los factores medioambientales. Métodos: se investigó a 50 niños con manifestaciones atópicas menores, mediante exploración clínica, analítica y pruebas epidérmicas e intradérmicas (true test, ácaros, alimentos). Conclusiones: los criterios menores parecen ser indicadores de la constitución atópica más que del eccema atópico; en éste, el medio ambiente y la herencia influyen de forma importante. Los eosinófilos y la IgE no se relacionaron con la intensidad del proceso cutáneo, sino con la intensidad del proceso respiratorio y la reactividad a los ácaros. Los alimentos no tuvieron relación con las manifestaciones cutáneas (AU)